Monogram Orthopaedics Inc
NASDAQ:MGRM
Monogram Orthopaedics Inc
Monogram Orthopaedics Inc is a US-based company operating in industry. The company is headquartered in Brooklyn, New York. The company went IPO on 2023-05-18. Monogram Orthopaedics Inc. (Monogram) is engaged in developing a product solution architecture for mass personalization of orthopedic implants by linking three-dimensional (3D) printing and robotics via automated digital image analysis algorithms. Its primary business is to market orthopedic implants insertable with its orthopedic robot. The company has a navigated robot prototype that can optically track a simulated surgical target and execute optimized auto-generated cut paths for precision insertion of implants in synthetic bone specimens. These implants and cut paths are generated with Monogram software algorithms. The Monogram technology platform consists of a workflow to prepare a patient-specific surgical plan from a computed tomography scan. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Monogram Orthopaedics Inc is a US-based company operating in industry. The company is headquartered in Brooklyn, New York. The company went IPO on 2023-05-18. Monogram Orthopaedics Inc. (Monogram) is engaged in developing a product solution architecture for mass personalization of orthopedic implants by linking three-dimensional (3D) printing and robotics via automated digital image analysis algorithms. Its primary business is to market orthopedic implants insertable with its orthopedic robot. The company has a navigated robot prototype that can optically track a simulated surgical target and execute optimized auto-generated cut paths for precision insertion of implants in synthetic bone specimens. These implants and cut paths are generated with Monogram software algorithms. The Monogram technology platform consists of a workflow to prepare a patient-specific surgical plan from a computed tomography scan. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Major Milestones: Monogram received FDA 510(k) clearance for its mBos Total TKA system and Indian regulatory approval to begin a multicenter clinical trial.
Clinical Progress: First live patient surgeries in India are expected within 90 business days; initial U.S. pilot placement targeted for Q3 2025.
System Improvements: Significant hardware and software upgrades have increased robot speed and accuracy since the FDA submission.
Financial Position: Cash balance of $13.3 million with a reduced monthly cash burn of $0.8 million, giving over a year of runway; no traditional debt.
Commercial Strategy: Company is taking a slow, methodical rollout with a focus on high system utilization and strong surgeon support.
Capital Needs: Additional capital will be needed to accelerate growth beyond the current conservative plan.
